Identification of Orthosteric and Allosteric Site Mutations in M2 Muscarinic Acetylcholine Receptors That Contribute to Ligand-selective Signaling Bias*
暂无分享,去创建一个
Arthur Christopoulos | Nathan E Hall | Patrick M Sexton | Andrew B Tobin | K. Gregory | P. Sexton | A. Christopoulos | A. Tobin | N. E. Hall | Karen J Gregory
[1] J. Wess,et al. Conformational Changes That Occur during M3Muscarinic Acetylcholine Receptor Activation Probed by the Use of an in Situ Disulfide Cross-linking Strategy* , 2002, The Journal of Biological Chemistry.
[2] A. Deutch,et al. Novel Selective Allosteric Activator of the M1 Muscarinic Acetylcholine Receptor Regulates Amyloid Processing and Produces Antipsychotic-Like Activity in Rats , 2008, The Journal of Neuroscience.
[3] K. Mohr,et al. Using a radioalloster to test predictions of the cooperativity model for gallamine binding to the allosteric site of muscarinic acetylcholine M(2) receptors. , 1999, Molecular pharmacology.
[4] C. Langmead,et al. Probing the Molecular Mechanism of Interaction between 4-n-Butyl-1-[4-(2-methylphenyl)-4-oxo-1-butyl]-piperidine (AC-42) and the Muscarinic M1 Receptor: Direct Pharmacological Evidence That AC-42 Is an Allosteric Agonist , 2006, Molecular Pharmacology.
[5] Arthur Christopoulos,et al. Critical Role for the Second Extracellular Loop in the Binding of Both Orthosteric and Allosteric G Protein-coupled Receptor Ligands* , 2007, Journal of Biological Chemistry.
[6] K. Mohr,et al. Interactions of orthosteric and allosteric ligands with [3H]dimethyl-W84 at the common allosteric site of muscarinic M2 receptors. , 2003, Molecular pharmacology.
[7] Arthur Christopoulos,et al. Orthosteric/allosteric bitopic ligands: going hybrid at GPCRs. , 2009, Molecular interventions.
[8] J. Wess,et al. Multiple Residues in the Second Extracellular Loop Are Critical for M3 Muscarinic Acetylcholine Receptor Activation* , 2007, Journal of Biological Chemistry.
[9] A. Christopoulos. Assessing the distribution of parameters in models of ligand-receptor interaction: to log or not to log. , 1998, Trends in pharmacological sciences.
[10] R. Abagyan,et al. Biased probability Monte Carlo conformational searches and electrostatic calculations for peptides and proteins. , 1994, Journal of molecular biology.
[11] Arthur Christopoulos,et al. A Novel Mechanism of G Protein-coupled Receptor Functional Selectivity , 2008, Journal of Biological Chemistry.
[12] Christopher J Langmead,et al. Mutagenic Mapping Suggests a Novel Binding Mode for Selective Agonists of M1 Muscarinic Acetylcholine Receptors , 2009, Molecular Pharmacology.
[13] C. Langmead,et al. Structure-Function Studies of Allosteric Agonism at M2 Muscarinic Acetylcholine Receptors , 2007, Molecular Pharmacology.
[14] U. Holzgrabe,et al. Dualsteric GPCR targeting: a novel route to binding and signaling pathway selectivity , 2009, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[15] R. Paschke,et al. Contacts between Extracellular Loop Two and Transmembrane Helix Six Determine Basal Activity of the Thyroid-stimulating Hormone Receptor* , 2007, Journal of Biological Chemistry.
[16] J. Vorlíček,et al. Positive cooperativity in the binding of alcuronium and N-methylscopolamine to muscarinic acetylcholine receptors. , 1990, Molecular pharmacology.
[17] P. Sexton,et al. Application of a Kinetic Model to the Apparently Complex Behavior of Negative and Positive Allosteric Modulators of Muscarinic Acetylcholine Receptors , 2004, Journal of Pharmacology and Experimental Therapeutics.
[18] U. Hacksell,et al. Discovery of an ectopic activation site on the M(1) muscarinic receptor. , 2002, Molecular pharmacology.
[19] Richard M. Eglen,et al. Muscarinic acetylcholine receptors: mutant mice provide new insights for drug development , 2007, Nature Reviews Drug Discovery.
[20] C. Felder. Muscarinic acetylcholine receptors: signal transduction through multiple effectors , 1995, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[21] R. Eglen,et al. Therapeutic opportunities from muscarinic receptor research. , 2001, Trends in pharmacological sciences.
[22] J. Proska,et al. Positive allosteric action of eburnamonine on cardiac muscarinic acetylcholine receptors. , 1996, European journal of pharmacology.
[23] E C Hulme,et al. The Functional Topography of Transmembrane Domain 3 of the M1 Muscarinic Acetylcholine Receptor, Revealed by Scanning Mutagenesis* , 1999, The Journal of Biological Chemistry.
[24] Roberto Maass-Moreno,et al. Fitting Models to Biological Data Using Linear and Nonlinear Regression: A Practical Guide to Curve Fitting.ByHarvey Motulskyand, Arthur Christopoulos.Oxford and New York: Oxford University Press. $65.00 (hardcover); $29.95 (paper). 351 p; ill.; index. ISBN: 0–19–517179–9 (hc); 0–19–517180–2 (pb). 2 , 2005 .
[25] Zhi-Liang Lu,et al. Scanning mutagenesis studies of the M1 muscarinic acetylcholine receptor. , 2003 .
[26] F. Mitchelson,et al. THE INHIBITORY EFFECT OF GALLAMINE ON MUSCARINIC RECEPTORS , 1976, British journal of pharmacology.
[27] K. Jakobs,et al. Activation of solubilized G-proteins by muscarinic acetylcholine receptors. , 1992, Cellular signalling.
[28] Kenneth A. Jacobson,et al. The Role of Amino Acids in Extracellular Loops of the Human P2Y1 Receptor in Surface Expression and Activation Processes* , 1999, The Journal of Biological Chemistry.
[29] E. Hulme,et al. Alanine-scanning mutagenesis of transmembrane domain 6 of the M(1) muscarinic acetylcholine receptor suggests that Tyr381 plays key roles in receptor function. , 1999, Molecular pharmacology.
[30] H Gobind Khorana,et al. Rhodopsin structure, dynamics, and activation: a perspective from crystallography, site-directed spin labeling, sulfhydryl reactivity, and disulfide cross-linking. , 2003, Advances in protein chemistry.
[31] K. Gregory,et al. Allosteric Modulation of Muscarinic Acetylcholine Receptors , 2007, Current neuropharmacology.
[32] Xi-Ping Huang,et al. Critical Amino Acid Residues of the Common Allosteric Site on the M2 Muscarinic Acetylcholine Receptor: More Similarities than Differences between the Structurally Divergent Agents Gallamine and Bis(ammonio)alkane-Type Hexamethylene-bis-[dimethyl-(3-phthalimidopropyl)ammonium]dibromide , 2005, Molecular Pharmacology.
[33] W. Sadee,et al. Allosteric modulation of muscarinic receptor signaling: alcuronium-induced conversion of pilocarpine from an agonist into an antagonist. , 2002, The Journal of pharmacology and experimental therapeutics.
[34] O. Wassermann,et al. Inhibition of the actions of carbachol and DFP on guinea pig isolated atria by alkane-bis-ammonium compounds. , 1969, European journal of pharmacology.
[35] P. Sexton,et al. Mechanisms of ERK1/2 regulation by seven-transmembrane-domain receptors. , 2006, Current pharmaceutical design.
[36] B. Roth,et al. New Insights into the Function of M4 Muscarinic Acetylcholine Receptors Gained Using a Novel Allosteric Modulator and a DREADD (Designer Receptor Exclusively Activated by a Designer Drug) , 2008, Molecular Pharmacology.
[37] A. Christopoulos,et al. Cellular Signaling Mechanisms for Muscarinic Acetylcholine Receptors , 2003 .
[38] C. Langmead,et al. Allosteric agonists of 7TM receptors: expanding the pharmacological toolbox. , 2006, Trends in pharmacological sciences.
[39] J. Wess,et al. Functional role in ligand binding and receptor activation of an asparagine residue present in the sixth transmembrane domain of all muscarinic acetylcholine receptors. , 1994, The Journal of biological chemistry.
[40] John Ellis,et al. Mutational Disruption of a Conserved Disulfide Bond in Muscarinic Acetylcholine Receptors Attenuates Positive Homotropic Cooperativity between Multiple Allosteric Sites and Has Subtype-Dependent Effects on the Affinities of Muscarinic Allosteric Ligands , 2007, Molecular Pharmacology.
[41] U. Holzgrabe,et al. Allosteric Small Molecules Unveil a Role of an Extracellular E2/Transmembrane Helix 7 Junction for G Protein-coupled Receptor Activation* , 2007, Journal of Biological Chemistry.
[42] S. Lazareno,et al. Probing of the location of the allosteric site on m1 muscarinic receptors by site-directed mutagenesis. , 1995, Molecular pharmacology.
[43] J. Black,et al. Operational models of pharmacological agonism , 1983, Proceedings of the Royal Society of London. Series B. Biological Sciences.
[44] P Ghanouni,et al. Agonist-induced conformational changes in the G-protein-coupling domain of the β2 adrenergic receptor , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[45] H. Khorana,et al. Requirement of Rigid-Body Motion of Transmembrane Helices for Light Activation of Rhodopsin , 1996, Science.
[46] H. Tecle,et al. Mutations of aspartate 103 in the Hm2 receptor and alterations in receptor binding properties of muscarinic agonists. , 1995, Life sciences.
[47] K. Page,et al. Scanning mutagenesis identifies amino acid side chains in transmembrane domain 5 of the M(1) muscarinic receptor that participate in binding the acetyl methyl group of acetylcholine. , 2000, Molecular pharmacology.
[48] J. Ellis,et al. Site-directed mutagenesis reveals two epitopes involved in the subtype selectivity of the allosteric interactions of gallamine at muscarinic acetylcholine receptors. , 1999, Molecular pharmacology.
[49] H Weinstein,et al. Agonists induce conformational changes in transmembrane domains III and VI of the β2 adrenoceptor , 1997, The EMBO journal.
[50] P. Sexton,et al. Molecular Mechanisms of Action and In Vivo Validation of an M4 Muscarinic Acetylcholine Receptor Allosteric Modulator with Potential Antipsychotic Properties , 2010, Neuropsychopharmacology.
[51] Arthur Christopoulos,et al. Functional Selectivity and Classical Concepts of Quantitative Pharmacology , 2007, Journal of Pharmacology and Experimental Therapeutics.
[52] S. Lazareno,et al. Detection, quantitation, and verification of allosteric interactions of agents with labeled and unlabeled ligands at G protein-coupled receptors: interactions of strychnine and acetylcholine at muscarinic receptors. , 1995, Molecular pharmacology.
[53] Thomas M Frimurer,et al. Overlapping Binding Site for the Endogenous Agonist, Small-Molecule Agonists, and Ago-allosteric Modulators on the Ghrelin Receptor , 2009, Molecular Pharmacology.
[54] J. Wess,et al. Use of an in situ disulfide cross-linking strategy to study the dynamic properties of the cytoplasmic end of transmembrane domain VI of the M3 muscarinic acetylcholine receptor. , 2006, Biochemistry.
[55] M. Brann,et al. Identification of a Ligand-dependent Switch within a Muscarinic Receptor* , 1998, The Journal of Biological Chemistry.
[56] R. Stevens,et al. High-Resolution Crystal Structure of an Engineered Human β2-Adrenergic G Protein–Coupled Receptor , 2007, Science.
[57] C. Strader,et al. Conserved aspartic acid residues 79 and 113 of the beta-adrenergic receptor have different roles in receptor function. , 1988, The Journal of biological chemistry.
[58] J. Wess,et al. Site‐directed mutagenesis of the m3 muscarinic receptor: identification of a series of threonine and tyrosine residues involved in agonist but not antagonist binding. , 1991, The EMBO journal.
[59] M. Whittington,et al. Characterization of a CNS penetrant, selective M1 muscarinic receptor agonist, 77‐LH‐28‐1 , 2008, British journal of pharmacology.
[60] F. Ehlert,et al. Estimation of the affinities of allosteric ligands using radioligand binding and pharmacological null methods. , 1988, Molecular pharmacology.
[61] C. Guenet,et al. Site-directed mutagenesis of the putative human muscarinic M2 receptor binding site. , 1999, European journal of pharmacology.
[62] J. Klco,et al. Essential role for the second extracellular loop in C5a receptor activation , 2005, Nature Structural &Molecular Biology.
[63] M. Eck,et al. Role of acidic amino acids in the allosteric modulation by gallamine of antagonist binding at the m2 muscarinic acetylcholine receptor. , 1994, Molecular pharmacology.
[64] J. Wess,et al. Pronounced Conformational Changes following Agonist Activation of the M3 Muscarinic Acetylcholine Receptor* , 2005, Journal of Biological Chemistry.
[65] K. Gregory,et al. Characterization of serotonin 5‐HT2C receptor signaling to extracellular signal‐regulated kinases 1 and 2 , 2005, Journal of neurochemistry.
[66] K. Mohr,et al. Allosteric Interactions with Muscarinic Acetylcholine Receptors: Complex Role of the Conserved Tryptophan M2422Trp in a Critical Cluster of Amino Acids for Baseline Affinity, Subtype Selectivity, and Cooperativity , 2006, Molecular Pharmacology.
[67] John Ellis,et al. Allosteric site on muscarinic acetylcholine receptors: identification of two amino acids in the muscarinic M2 receptor that account entirely for the M2/M5 subtype selectivities of some structurally diverse allosteric ligands in N-methylscopolamine-occupied receptors. , 2003, Molecular pharmacology.
[68] Y. Cheng,et al. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. , 1973, Biochemical pharmacology.
[69] J. Ballesteros,et al. [19] Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G protein-coupled receptors , 1995 .
[70] N. Birdsall,et al. Propylbenzilylcholine mustard labels an acidic residue in transmembrane helix 3 of the muscarinic receptor. , 1989, The Journal of biological chemistry.
[71] M. Brann,et al. Use of chimeric muscarinic receptors to investigate epitopes involved in allosteric interactions. , 1993, Molecular pharmacology.
[72] K. Mohr,et al. Allosteric site on muscarinic acetylcholine receptors: a single amino acid in transmembrane region 7 is critical to the subtype selectivities of caracurine V derivatives and alkane-bisammonium ligands. , 2002, Molecular pharmacology.
[73] L. Bačáková,et al. Subtype selectivity of the positive allosteric action of alcuronium at cloned M1-M5 muscarinic acetylcholine receptors. , 1995, The Journal of pharmacology and experimental therapeutics.
[74] P. Jeffrey Conn,et al. N-desmethylclozapine, an allosteric agonist at muscarinic 1 receptor, potentiates N-methyl-d-aspartate receptor activity , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[75] J. Wess,et al. Distinct Structural Changes in a G Protein-coupled Receptor Caused by Different Classes of Agonist Ligands* , 2007, Journal of Biological Chemistry.
[76] J W Saldanha,et al. Transmembrane Domains 4 and 7 of the M1Muscarinic Acetylcholine Receptor Are Critical for Ligand Binding and the Receptor Activation Switch* , 2001, The Journal of Biological Chemistry.
[77] G. Liapakis,et al. Constitutive Activation of the β2 Adrenergic Receptor Alters the Orientation of Its Sixth Membrane-spanning Segment* , 1997, The Journal of Biological Chemistry.
[78] H. Khorana,et al. Structure and function in rhodopsin: replacement by alanine of cysteine residues 110 and 187, components of a conserved disulfide bond in rhodopsin, affects the light-activated metarhodopsin II state. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[79] M. Brann,et al. Structural Requirements of Transmembrane Domain 3 for Activation by the M1 Muscarinic Receptor Agonists AC-42, AC-260584, Clozapine, and N-Desmethylclozapine: Evidence for Three Distinct Modes of Receptor Activation , 2006, Molecular Pharmacology.